Meglucon Xr (Metformin Hydrochloride)

Metformin lowers blood sugar by inhibiting hepatic glucose production and enhancing peripheral insulin sensitivity. It activates AMP‑activated protein kinase (AMPK), which reduces gluconeogenesis and increases glucose uptake in muscle and fat tissues without stimulating insulin release.

The dosage of Meglucon Xr is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of metformin during pregnancy or lactation should be evaluated by a qualified clinician. While some guidelines allow its use in certain pregnant patients with diabetes, the decision depends on risk‑benefit assessment. Breastfeeding mothers should consult their doctor before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Meglucon Xr (metformin) belongs to the biguanide class and is often first‑line therapy for type 2 diabetes because it does not cause weight gain and has a low risk of hypoglycaemia compared with sulfonylureas or insulin. Its efficacy and safety profile differ from newer agents such as SGLT2 inhibitors or GLP‑1 receptor agonists.

Store Meglucon Xr at ambient temperature, preferably below 25 °C, in the original container to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date.

Meglucon Xr is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious potential risk is lactic acidosis, a rare but life‑threatening condition that can occur in patients with severe renal impairment, hepatic disease, or significant hypoxia. Other serious concerns include severe skin reactions and vitamin B12 deficiency with prolonged therapy.

Meglucon Xr should be avoided in patients with known hypersensitivity to metformin, severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with conditions that predispose to hypoxia such as severe heart or respiratory failure.